EN
EN
FR
ES
PT
AR
RU
DE
IT
NL
TH
KO
VI
ID
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
Synthetic Biology
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium Butyricum and Bifidobacterium Capsule, Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Aflibercept Intravitreous Injection
Denosumab
Enzalutamide Soft Capsules
Sitagliptin Phosphate Tablets
Liraglutide Injection
Sevelamer Carbonate Tablets
Olaparib Tablets
Sorafenib Tablets
Eribulin Mesylate Injection
Neratinib Maleate Tablets
Lenalidomide Capsules
Trastuzumab Injection
Palbociclib Capsules
Semaglutide Injection
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and Innovation
Video Center
Contact
Contact Us
Join Us
NEWS AND INFORMATION
Home
/
Kexing Biopharm...
Kexing Biopharm Product Introduction-20251023
Article source：
Oct 22,2025
View： 657
LABEL:
< Kexing Biopharm's Product Introduction 20251021
Kexing Biopharm Product List-20251023 >
BACK TO LIST
Related News
Oct 17,2025
Kexing Biopharm and Easton Biopharmaceuticals Jointly Expand Overseas Market for Apalutamide Tablets
READ MORE >>
Oct 22,2025
Kexing Biopharm's Product Introduction 20251021
READ MORE >>
Dec 11,2025
Kexing Biopharm's Independently Developed Ophthalmic Innovative Drug GB10 Receives Clinical Trial Approval
READ MORE >>
Jun 06,2024
Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone
READ MORE >>
Jul 13,2023
Led by Sci-tech Innovation, Expanding into Global Markets — Kexing Biopharm in International Exhibitions
READ MORE >>
Nov 11,2025
Kexing Biopharm's Ophthalmic Innovative Drug GB10 Research Featured in Prestigious International Journal
READ MORE >>
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
Synthetic Biology
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium Butyricum and Bifidobacterium Capsule, Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Aflibercept Intravitreous Injection
Denosumab
Enzalutamide Soft Capsules
Sitagliptin Phosphate Tablets
Liraglutide Injection
Sevelamer Carbonate Tablets
Olaparib Tablets
Sorafenib Tablets
Eribulin Mesylate Injection
Neratinib Maleate Tablets
Lenalidomide Capsules
Trastuzumab Injection
Palbociclib Capsules
Semaglutide Injection
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and Innovation
Video Center
Contact
Contact Us
Join Us
Article source：
Oct 22,2025
View：
657 
BACK TO LIST
Oct 17,2025
